Japanese patent, European classification, Significantly positive...

Japanese patent,
European classification,
Significantly positive results for Phase I trials,
Japanese Partner,
Japanese Director.

RGS is not the most exciting biotech when it comes to communication, but it's hard to deny they deliver on promises.

And all financial indicators are now very positive, creating the opportunity to finance (borrow?) their commercialisation plan in Japan and Europe: communication, marketing, sales.

Well done.